Five Prime Therapeutics (FPRX) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
November 6, 2018 4:05 PM ESTInitiated Phase 3 FIGHT global registrational trial of bemarituzumab in gastric and gastroesophageal junction (GEJ) cancer Initiated FPA150 dosing in B7-H4 positive patients in Phase 1 exploratory cohort Opened enrollment for the FPT155 Phase 1 clinical trial in Australia Announced industry veteran David V. Smith will join as Executive Vice President and Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--... More
